Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

Craft Capital Management LLC acted as underwriter for the Offering (the “Underwriter”). VCL Law LLP acted as U.S. securities counsel to the Company, and Ortoli Rosenstadt LLP acted as U.S. securities ...

Greenhaven Road Capital, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the ...

With more than three weeks left in the first quarter, the value of med-tech IPOs for 2025 already exceeds the funds raised ...

Advanced Biomed Inc. (the “Company” or “Advanced Biomed”), a biotechnology company focused on early screening and detection, diagnosis and staging, and treatment of cancer, today announced the pricing ...

Signs a strategic collaboration and license agreement to advance novel therapies targeting corticotropin-releasing hormone (CRH) for various disorders.

"The sale of Celios® to Impact BioMedical represents another step in our strategic efforts to streamline our holdings and focus on our core business objectives,” said Jason Grady, CEO of DSS, Inc.

This week, Advanced Biomed (ADVB) is looking to raise $112M under its initial public offering. The company is developing a portfolio of cancer screening technologies for the Chinese market.